Scotland: Are Orphan Medicines Over Incentivized?
Over the years, pharmaceutical companies in Europe have been given more incentives to develop orphan drugs, such as 10 years of market exclusivity. But with numbers of orphans on the rise, has the pendulum swung the other way?
You may also be interested in...
Novo Nordisk Hit With UK Industry Association Suspension Over Weight Loss Drug Promotion
Novo Nordisk has been hit by a serious sanction in the UK after having been found to effectively pay pharmacists to promote Saxenda.
UK ABPI Suspends Novo Nordisk Over Code Breach
Novo Nordisk has been given a two-year suspension from membership of the Association of the British Pharmaceutical Industry for breaching the association’s code of practice.
BMS Decides Against Opdualag Launch In Germany
BMS says that recent reforms to the benefit assessment system have led to the “deterioration” of the German market.